ArticleBMC cancer2014

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.

Jeetendra Eswaraka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.